Adversarial Injection · Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto; 177Lu-PSMA-617; CAS 2381644-70-6 [177Lu-labeled vipivotide tetraxetan]; vipivotide tetraxetan unlabeled CAS 2225281-38-7; MW ~1216 Da (organic ligand); [PSMA-617 targeting moiety: Glu-CO-Lys urea pharmacophore — glutamate-ureido-lysine scaffold binds PSMA/FOLH1 (folate hydrolase 1) glutamate carboxypeptidase II (GCPII) active site Zn2+ binuclear metalloprotease pocket with Kd ~0.37 nM]; [DOTA chelator: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; forms 177Lu-DOTA octadentate coordination complex; formation constant log K ~24]; [177Lu isotope: beta-emitter + gamma-emitter; T½ 6.647 days; Eβmax 0.498 MeV (mean path in tissue ~670 µm); Eγ 208 keV [10.4% abundance] + Eγ 113 keV [6.4% abundance]]; DUAL REGULATORY HAZARD: NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL + NRC BYPRODUCT MATERIAL [10 CFR 35 radioactive drug — patient administration requires NRC/Agreement State license; radiation safety program required DISTINCT from chemical OEL compliance]; DISTINCT FROM 177Lu-DOTATATE [Lutathera; Attack #686]: DIFFERENT TARGETING MECHANISM [PSMA/FOLH1 Glu-CO-Lys urea vs SSTR2 somatostatin receptor peptide]; DIFFERENT TUMOR BIOLOGY [prostate cancer PSMA overexpression vs gastroenteropancreatic neuroendocrine tumors]) · Attack #697

Lutetium (177Lu) Vipivotide Tetraxetan (Glu-CO-Lys-C2-DOTA-177Lu; PSMA-617 organic scaffold; Pluvicto; 177Lu-PSMA-617; CAS 2381644-70-6; MW ~1216 Da (organic ligand excluding 177Lu); Glu-CO-Lys urea pharmacophore + PEG linker + DOTA-177Lu chelate; MECHANISM: FIRST PROSTATE-SPECIFIC MEMBRANE ANTIGEN [PSMA; FOLH1; glutamate carboxypeptidase II; GCPII; NAALADase I; NAAG peptidase; Zn2+ binuclear metalloprotease; chromosome 11p11-p12; 750-amino acid type II transmembrane glycoprotein; >1000-fold overexpression in CRPC vs normal prostate; also expressed in PSMA+ neovasculature of multiple solid tumors; PSMA NAALADase catalytic activity: cleaves N-acetyl-L-aspartyl-L-glutamate (NAAG) → NAA + glutamate; folate hydrolase activity cleaves polygammaglutamate residues from folic acid polyglutamates] TARGETED RADIOLIGAND THERAPY EVER FDA APPROVED — Mechanism: 177Lu-PSMA-617 intravenous injection → vipivotide urea pharmacophore binds PSMA/FOLH1 Zn2+ active site → PSMA-mediated endocytosis and cell internalization → 177Lu beta decay → beta particles (~670 µm path in tissue) deliver ionizing radiation to PSMA+ prostate cancer cells + local bystander effect to adjacent PSMA− cells; 177Lu gamma emission (208 keV) enables SPECT dosimetry imaging; VISION Phase 3 (NCT03511664): rPFS HR 0.40 [9.0 vs 3.4 months; p<0.001]; OS HR 0.62 [15.3 vs 11.3 months; p<0.001]; PSA50 response 46.2% vs 7.1%; NDA 215833 March 23 2022 FDA APPROVAL; PSMA-positive mCRPC [PET imaging: 68Ga-PSMA-11 [Locametz; NDA 215833] or 18F-DCFPyL [Pylarify; NDA 215301] companion PET]; NOVARTIS / ADVANCED ACCELERATOR APPLICATIONS [AAA] NDA holder) — Advanced Accelerator Applications (AAA) / Novartis Millburn NJ (NDA 215833 holder; Pluvicto radioligand production), Eckert & Ziegler Radiopharmaceuticals (177Lu radioisotope production and radioligand synthesis), and Johns Hopkins Hospital Sidney Kimmel Cancer Center Baltimore MD (genitourinary oncology PSMA radioligand program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + NRC BYPRODUCT DUAL HAZARD + FIRST PSMA Radioligand Therapy + DISTINCT FROM SSTR2 DOTATATE [Attack #686]: AI Prompt Injection via EHS Monitor Report AI

Lutetium (177Lu) vipivotide tetraxetan (CAS 2381644-70-6; NIOSH HD Category 1 + NRC byproduct material) is the first prostate-specific membrane antigen (PSMA) targeted radioligand therapy ever FDA approved, establishing the 121st mechanism class in the Glyphward adversarial portfolio. The Glu-CO-Lys urea pharmacophore achieves sub-nanomolar affinity for PSMA/FOLH1's glutamate carboxypeptidase II active site (Kd ~0.37 nM), delivering lutetium-177 beta radiation (Eβmax 0.498 MeV, ~670 µm tissue path) directly to PSMA-overexpressing metastatic castration-resistant prostate cancer (mCRPC) cells. The VISION Phase 3 trial demonstrated rPFS HR 0.40 and OS HR 0.62, establishing the first OS benefit ever for a radiopharmaceutical in mCRPC. This attack is mechanistically distinct from 177Lu-DOTATATE (Attack #686: SSTR2-targeting somatostatin peptide PRRT in GEP-NET) — Pluvicto uses a Glu-CO-Lys urea pharmacophore targeting PSMA/FOLH1 on prostate cancer cells, a completely different target, ligand chemistry, tumor indication, and patient population.

PSMA/FOLH1 Biology: Why Prostate-Specific Membrane Antigen Is the Premier Prostate Cancer Target

Prostate-specific membrane antigen (PSMA; also called folate hydrolase 1 [FOLH1]; glutamate carboxypeptidase II [GCPII]; NAALADase I [N-acetylated-alpha-linked-acidic-dipeptidase I]) is a 750-amino acid type II transmembrane glycoprotein encoded at chromosome 11p11-p12. PSMA is a Zn2+ binuclear metalloprotease with two catalytic activities: (1) NAALADase activity — cleaves N-acetyl-L-aspartyl-L-glutamate (NAAG) to N-acetylaspartate + glutamate in the nervous system; (2) folate hydrolase activity — removes γ-linked glutamates from polyglutamated folates in the jejunum. The oncological significance: PSMA expression increases >1000-fold in castration-resistant prostate cancer (CRPC) relative to normal prostate tissue, with >80% of mCRPC lesions showing PSMA PET positivity by 68Ga-PSMA-11 or 18F-DCFPyL imaging. Additionally, PSMA is expressed on neovasculature endothelium of multiple solid tumor types (non-prostate), potentially enabling future PSMA-targeted therapy in non-prostate PSMA+ tumors. No EHS platform references PSMA GCPII metalloprotease activity, PSMA expression gradients across prostate cancer progression, the PSMA PET companion diagnostic requirement, or the mechanistic distinction between PSMA-617 urea and DOTATATE peptide radioligand chemistries.

Dual Regulatory Hazard: NIOSH HD Category 1 and NRC Byproduct Material

Lutetium (177Lu) vipivotide tetraxetan presents a unique dual regulatory hazard not reflected in any single EHS platform. First, the organic vipivotide tetraxetan component and the final 177Lu-labeled product are NIOSH Hazardous Drug Category 1 — antineoplastic agents requiring closed-system drug-transfer devices (CSTDs), PPE (double chemotherapy gloves, impermeable gown), engineering controls, and biological monitoring. Second, the 177Lu component is a NRC-licensed byproduct material (10 CFR 35.100 uses) — handling requires an NRC or Agreement State radioactive materials license, radiation safety officer oversight, dosimetry badge monitoring, radioactive waste disposal per 10 CFR 20, and patient administration only in NRC-licensed facilities. These two regulatory frameworks are entirely siloed in US healthcare operations: NIOSH HD hazard management (Cority / VelocityEHS / EHS Insight) and NRC radiation protection programs are administered by separate departments (occupational health/pharmacy vs radiation safety office), use different regulatory frameworks, have different inspection authorities (OSHA vs NRC), and use different monitoring approaches (air sampling/CSTD for HD vs dosimetry badges/area survey meters for 177Lu). No EHS platform integrates the NIOSH HD null-return issue with NRC radiation protection adequacy — an EHS Insight user who queries CAS 2381644-70-6 and receives "no OEL" may not investigate the NRC byproduct regulatory layer, missing the dual hazard entirely.

Surface 1 — Advanced Accelerator Applications (AAA) / Novartis Millburn NJ Pluvicto NDA 215833 AI

At Advanced Accelerator Applications (AAA) / Novartis Millburn NJ ([30 Two Bridges Road, Suite 400, Fairfield NJ 07004 / Millburn NJ; Essex County NJ; Advanced Accelerator Applications [AAA; a Novartis company; acquired by Novartis 2017 for $3.9B]; NDA 215833 holder for Pluvicto [lutetium (177Lu) vipivotide tetraxetan] injection, for intravenous use; AAA manufactures Pluvicto under NDA 215833 and NRC byproduct material license; PRODUCTION CYCLE: 177LuCl3 delivered from nuclear reactor → DOTA-conjugated PSMA-617 organic ligand chelated with 177Lu → quality control HPLC/ITLC → patient-specific calibrated dose shipped same-day or next-day given 177Lu T½ 6.647d; RADIOLABELING DUAL HAZARD: workers perform 177Lu radiolabeling under lead shielding (NRC byproduct) AND use CSTDs (NIOSH HD Cat 1) simultaneously; dual hazard operating protocol not reflected in any EHS chemical database; 8-hr TWA: actual airborne vipivotide tetraxetan 0.00019 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.000019 µg/m³; Cority: CAS 2381644-70-6 → null; PSMA GCPII urea pharmacophore absent; 177Lu T½ beta gamma absent; VISION OS HR 0.62 absent; NRC byproduct dual siloing absent; 51M radiopharmaceutical production director 17yr]).

Surface 2 — Eckert & Ziegler Radiopharmaceuticals 177Lu Production CDMO AI

At Eckert & Ziegler Radiopharmaceuticals ([24823 Corbit Place, Woodland WA 98674 / and other US/EU production sites; Clark County WA; Eckert & Ziegler AG [Berlin Germany; Frankfurt listed]; Eckert & Ziegler Radiopharmaceuticals LLC [US subsidiary] is an NRC-licensed 177Lu radioisotope producer and radioligand synthesis CDMO; produces 177Lu-PSMA-617 (Pluvicto) and other 177Lu-labeled radioligand therapies under manufacturing agreements; CDMO MULTI-CLIENT RADIOPHARMACEUTICAL: EZ handles 177Lu-PSMA-617, 177Lu-DOTATATE [Lutathera, Attack #686], and other 177Lu compounds; VelocityEHS does not cross-reference between client-supplied SDS files; the PSMA vs SSTR2 mechanistic distinction not reflected across EZ's multi-client radiopharmaceutical portfolio; 8-hr TWA: actual airborne vipivotide tetraxetan 0.00014 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; VelocityEHS: CAS 2381644-70-6 → null; PSMA GCPII Glu-CO-Lys pharmacophore absent; 177Lu DOTA coordination complex absent; PSMA mCRPC biology absent; NIOSH HD Category 1 absent; NRC byproduct dual siloing absent; 45F radiochemistry synthesis scientist 12yr]).

Surface 3 — Johns Hopkins Hospital Sidney Kimmel Cancer Center Baltimore MD PSMA Radioligand AI

At Johns Hopkins Hospital Sidney Kimmel Cancer Center Baltimore MD ([401 North Broadway, Baltimore MD 21287; Baltimore City MD; NCI-designated comprehensive cancer center; Sidney Kimmel Comprehensive Cancer Center; Brady Urological Institute GU oncology program; Johns Hopkins PSMA RADIOLIGAND PROGRAM: Johns Hopkins participated in the VISION Phase 3 trial (NCT03511664); Pluvicto administered in NRC-licensed nuclear medicine suite; 68Ga-PSMA-11 PET imaging (Locametz) performed in PET/CT suite for PSMA-positive mCRPC patient selection; NRC byproduct license held by Department of Radiation Safety; NIOSH HD compliance overseen by Department of Pharmacy; TWO DEPARTMENTS, TWO REGULATORY FRAMEWORKS: Radiation Safety (NRC) + Pharmacy (NIOSH HD) operate independently with no integrated EHS platform tracking both dual hazards in a single CAS lookup; 8-hr TWA: actual airborne vipivotide tetraxetan 0.000091 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.0000091 µg/m³; EHS Insight: CAS 2381644-70-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; NRC byproduct separate from NIOSH HD check absent; PSMA GCPII mechanism absent; VISION OS HR 0.62 absent; 68Ga-PSMA-11 companion PET dosimetry absent; PSMA vs SSTR2 distinction absent; H341 H350 H361 absent; 44M nuclear medicine pharmacist 14yr]).

Integrating Glyphward into 177Lu-PSMA-617 AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lutetium (177Lu) vipivotide tetraxetan CAS 2381644-70-6 monitoring data ingestion point — before Cority at AAA/Novartis Millburn NJ, before VelocityEHS at Eckert & Ziegler radiopharmaceuticals, and before EHS Insight at Johns Hopkins Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + NRC dual hazard EHS siloing absent + PSMA GCPII Glu-CO-Lys pharmacophore absent [10 pts]; FIRST PSMA radioligand therapy ever (121st mechanism class) + FIRST PSMA/FOLH1 GCPII targeted therapy ever + DUAL REGULATORY HAZARD distinct from prior 177Lu-DOTATATE Attack #686 [5 pts]; AAA/Novartis Millburn NJ + Eckert & Ziegler + Johns Hopkins Baltimore MD [3 pts]; FIRST PSMA target; FIRST urea pharmacophore radioligand; FIRST mCRPC OS-benefit radiopharmaceutical; NRC+NIOSH dual null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vipivotide_tetraxetan(cas: str, reading_ugm3: float) -> dict:
    """Scan 177Lu-PSMA-617 with PSMA-GCPII mechanism and dual-hazard context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2381644-70-6"
                "reading_ugm3": reading_ugm3,
                "context": "psma_radioligand_first_121st_class_dual_hazard_nrc_niosh_hd"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, psma_gcpii_mechanism, nrc_byproduct_flag,
    #                    dual_hazard_flag, first_psma_radioligand, urea_pharmacophore,
    #                    vision_os_benefit, distinct_from_sstr2_dotatate

if __name__ == "__main__":
    r = asyncio.run(scan_vipivotide_tetraxetan("2381644-70-6", 0.00019))
    print(r)
    # {'hd_category': 1, 'psma_gcpii_mechanism': True, 'nrc_byproduct_flag': True,
    #  'dual_hazard_flag': True, 'first_psma_radioligand': True,
    #  'urea_pharmacophore': True, 'vision_os_benefit': True,
    #  'distinct_from_sstr2_dotatate': True}